đź’¨ Abstract
Alnylam Pharmaceuticals Inc. reported a Q1 loss of $57.5 million, with a loss of 44 cents per share. Adjusted losses were 1 cent per share, beating Wall Street expectations. Revenue was $594.2 million, also surpassing estimates. The RNA interference drug developer's shares have risen 12% this year and 83% over the past 12 months.
Courtesy: wtop.com
Summarized by Einstein Beta 🤖
Suggested
Court sides with Fortnite maker Epic as Apple sanctioned for defying order in App Store case -
Road to Garcia-Haney rematch runs through Times Square, where both box Friday in famed New York spot -
Unión de Usuarios y Consumidores: “Vemos que mucha gente se está endeudando para poder pagar los servicios públicos” -
Barcelona gets chance to rest top players against already relegated Valladolid -
The Justice Department ended a decades-old school desegregation order. Others are expected to fall -
En fallo inédito, juez designado por Trump dice que uso de la Ley de Enemigos Extranjeros por parte del presidente es ilegal -
Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health -
Mother of dead inmate sues troubled Wisconsin prison where 7 have died since 2023 -
California Republicans, moderate Dems push for harsher penalties for soliciting sex from older teens -
Harvey Weinstein’s lawyers get their turn to question accuser Miriam Haley at #MeToo retrial -
Powered by MessengerX.io